Key result
Targeted angiopoietin-2 inhibition with RNA aptamers or blocking antibodies is a potential anti-inflammatory and anti-vascular hyperpermeability strategy in the treatment of sepsis and ALI/ARDS.
Why the study?
Does targeted angiopoietin-2 inhibition or angiopoietin-1 modulation improve outcomes in sepsis and acute lung injury/ARDS?
Does targeted angiopoietin-2 inhibition or angiopoietin-1 modulation improve outcomes in sepsis and acute lung injury/ARDS?
The angiopoietin-Tie2 system, specifically through angiopoietin-2 inhibition, represents a promising therapeutic target for reducing inflammation and vascular hyperpermeability in sepsis and ARDS.
Answers are grounded in this paper and cite their sources.
Angiopoietin-2 inhibition remains investigational in sepsis and ARDS; hypothesis-generating without prospective outcome data.
BACKGROUND: Sepsis and acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) are life-threatening syndromes characterised by inflammation and increased vascular permeability. Amongst other factors, the angiopoietin-tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) system is involved. OBJECTIVE: To explore whether the angiopoietin-Tie2 system provides suitable targets for the treatment of sepsis and ALI/ARDS. METHODS: Original experimental and patient studies on angiopoietins and sepsis/endotoxemia, inflammation, lung injury, hyperpermeability, apoptosis, organ functions and vital outcomes were reviewed. RESULTS/CONCLUSION: The angiopoietin-Tie2 system controls the responsiveness of the endothelium to inflammatory, hyperpermeability, apoptosis and vasoreactive stimuli. Angiopoietin-2 provokes inflammation and vascular hyperpermeability, while angiopoietin-1 has a protective effect. Targeted angiopoietin-2 inhibition with RNA aptamers or blocking antibodies is a potential anti-inflammatory and anti-vascular hyperpermeability strategy in the treatment of sepsis and ALI/ARDS.
No takes yet. Share an insight, caveat, or question.
Heijden et al. (2008) conducted a review in Sepsis and acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Targeted angiopoietin-2 inhibition was evaluated. Targeted angiopoietin-2 inhibition with RNA aptamers or blocking antibodies is a potential anti-inflammatory and anti-vascular hyperpermeability strategy in the treatment of sepsis and ALI/ARDS.
Synapse has enriched 10 related papers. Consider them for comparative context: